Clinical Trial Update: Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A safety and pharmacodynamic study of the AGI-101H vaccine for advanced melanoma has been terminated after Phase 1 and Phase 2 trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• AGI-101H vaccine (AGI-101H vaccine)

Snippet

Sponsor: AGIRx Ltd. | Conditions: Melanoma | Phase 1, Phase 2 | Status: TERMINATED